Philip F. Palmedo
resigned as a director of the Company due to health concerns, effective July 28, 2023.
Highest-materiality recent filing
Gyrodyne CEO provides operational update; Flowerfield parcel sale for $28.74M targeted end of 2027
Sold 49 undeveloped acres of Flowerfield to B2K Development for $28.74M; close expected end 2027 subject to litigation & approvals.
Gyrodyne settles with Star Equity; board reduced to four, Star Equity withdraws nominations
Star Equity withdraws June 4, 2025 board nominations; board size cut from five to four.
Gyrodyne signs agreement to sell 49-acre parcel for up to $28.74M; NAV per share rises to $14.83
Purchase price range $24M-$28.74M, estimated final price $28.74M; buyer B2K Smithtown LLC.
NY Supreme Court dismisses Article 78 petition against Gyrodyne's Flowerfield subdivision approval
On October 11, 2024, the NY Supreme Court ruled in favor of Gyrodyne, dismissing the Article 78 petition challenging the 8-lot subdivision of its Flowerfield property.
Rights offering oversubscribed 65%, net proceeds $4.4M to defend Article 78 litigation and negotiate from strength.
Gyrodyne closes oversubscribed rights offering, raises $5M gross
Gross proceeds of $5M from sale of 625,000 shares at $8 per share; net proceeds ~$4.4M.
Gyrodyne secures $1.5M term mortgage loan for working capital
Principal $1.5M from LLYR Resources, LLC; two-year term, floating rate at 1.5% above Wall Street Prime Rate.
Gyrodyne reports estimated NAV of $20.14/share, updates on entitlement delays and activist costs
Estimated liquidating value $20.14 per share at Q2 2023, up $4.61 from Dec 2021, driven by $11.1M real estate value increase.
Gyrodyne amends bonus plan; directors waive cash for 91,628 shares
Director participants waive bonus plan benefits for 91,628 shares under new Stock Plan, subject to shareholder approval.
Gyrodyne settles with Star Equity; adopts stock plan for directors, freezes fees
Gyrodyne will submit a new stock incentive plan to shareholders; $579,328 in director bonus benefits exchanged for shares.
Gyrodyne appoints Jan Loeb to board under cooperation agreement; Palmedo resigns
Cooperation Agreement with Leap Tide Capital Management; Loeb appointed and will be nominated for 2023 annual meeting.
Gyrodyne's Cortlandt Manor property rezoned as Medical Oriented District; sale planned
Town Board unanimously adopted SEQRA findings and approved MOD local law on March 20, 2023.
Gyrodyne CEO letter outlines progress on entitlements, targets dissolution by end of 2024
Total real estate assets $42.5M, debt $9.8M, loan-to-value 23% as of Q3 2022.
NAV per share $15.50 as of June 30, 2022, up $0.33 from Dec 31, 2020; real estate value up $3.99M offset by $3.5M higher liquidation costs.
Gyrodyne faces Article 78 lawsuit seeking to annul Flowerfield subdivision approval
Petitioners filed Article 78 petition April 26 in NY Supreme Court, Suffolk County, to annul Planning Board's preliminary subdivision approval.
Town of Smithtown Planning Board granted preliminary subdivision approval on March 30, 2022, subject to conditions including stormwater plan and SEQRA findings.
Gyrodyne NAV per share falls 28% to $15.22; progress on entitlements but timeline extended to 2022
NAV per share $15.22 at March 31, 2021, down 28% from $21.20 a year ago; pandemic blamed for terminated purchase agreements and delays.
resigned as a director of the Company due to health concerns, effective July 28, 2023.
appointed Jan H. Loeb to the Board to fill the vacancy on the Board created by Mr. Palmedo’s resignation
Max materiality 0.80 · Median 0.60 · Most common event other_material